Treskes Roderick W, Beles Monika, Caputo Maria-Luce, Cordon Audrey, Biundo Eliana, Maes Edith, Egorova Anastasia D, Schalij Martin J, Van Bockstal Koen, Grazioli-Gauthier Lorenzo, Vanderheyden Marc, Bartunek Jozef, Auricchio Angelo, Beeres Saskia L M A, Heggermont Ward A
Department of Cardiology, Leiden University Medical Centre, Leiden, The Netherlands.
Cardiovascular Center Aalst, Department of Cardiology, Onze Lieve Vrouw Hospital, Moorselbaan 164, Aalst, 9300, Belgium.
ESC Heart Fail. 2021 Apr;8(2):1541-1551. doi: 10.1002/ehf2.13252. Epub 2021 Feb 22.
The implantable cardiac defibrillator/cardiac resynchronization therapy with defibrillator-based HeartLogic™ algorithm has recently been developed for early detection of impending decompensation in heart failure (HF) patients; but whether this novel algorithm can reduce HF hospitalizations has not been evaluated. We investigated if activation of the HeartLogic algorithm reduces the number of hospital admissions for decompensated HF in a 1 year post-activation period as compared with a 1 year pre-activation period.
Heart failure patients with an implantable cardiac defibrillator/cardiac resynchronization therapy with defibrillator with the ability to activate HeartLogic and willingness to have remote device monitoring were included in this multicentre non-blinded single-arm trial with historical comparison. After a HeartLogic alert, the presence of HF symptoms and signs was evaluated. If there were two or more symptoms and signs apart from the HeartLogic alert, lifestyle advices were given and/or medication was adjusted. After activation of the algorithm, patients were followed for 1 year. HF events occurring in the 1 year prior to activation and in the 1 year after activation were compared. Of the 74 eligible patients (67.2 ± 10.3 years, 84% male), 68 patients completed the 1 year follow-up period. The total number of HF hospitalizations reduced from 27 in the pre-activation period to 7 in the post-activation period (P = 0.003). The number of patients hospitalized for HF declined from 21 to 7 (P = 0.005), and the hospitalization length of stay diminished from average 16 to 7 days (P = 0.079). Subgroup analysis showed similar results (P = 0.888) for patients receiving cardiac resynchronization therapy during the pre-activation period or not receiving cardiac resynchronization therapy, meaning that the effect of hospitalizations cannot solely be attributed to reverse remodelling. Subanalysis of a single-centre Belgian subpopulation showed important reductions in overall health economic costs (P = 0.025).
Activation of the HeartLogic algorithm enables remote monitoring of HF patients, coincides with a significant reduction in hospitalizations for decompensated HF, and results in health economic benefits.
植入式心脏除颤器/具备基于除颤器的HeartLogic™算法的心脏再同步治疗最近已被开发用于早期检测心力衰竭(HF)患者即将发生的失代偿情况;但这种新算法是否能减少HF住院治疗尚未得到评估。我们调查了与激活前1年相比,激活HeartLogic算法在激活后1年期间是否能减少失代偿性HF的住院次数。
本多中心非盲单臂试验采用历史对照,纳入了植入式心脏除颤器/具备激活HeartLogic能力且愿意接受远程设备监测的心脏再同步治疗的HF患者。在收到HeartLogic警报后,评估HF症状和体征的存在情况。如果除HeartLogic警报外还有两种或更多症状和体征,则给予生活方式建议和/或调整药物治疗。算法激活后,对患者进行1年的随访。比较激活前1年和激活后1年发生的HF事件。在74名符合条件的患者(67.2±10.3岁,84%为男性)中,68名患者完成了1年的随访期。HF住院总数从激活前期的27次降至激活后期的7次(P = 0.003)。因HF住院的患者人数从21人降至7人(P = 0.005),住院天数从平均16天减少到7天(P = 0.079)。亚组分析显示,激活前期接受心脏再同步治疗或未接受心脏再同步治疗的患者结果相似(P = 0.888),这意味着住院治疗效果不能完全归因于逆向重塑。对比利时一个单中心亚组的亚分析显示总体健康经济成本有显著降低(P = 0.025)。
激活HeartLogic算法可实现对HF患者的远程监测,同时显著减少失代偿性HF的住院次数,并带来健康经济效益。